8.3 Neonatal Arrhythmias, Cardiogenic Shock & Post-Resuscitation Care

Neonatal Arrhythmias, Cardiogenic Shock & Post-Resuscitation Care

Neonatal rhythm disturbances and low cardiac output states present complex diagnostic and therapeutic challenges during interfacility transport. The neonatal myocardium is structurally immature, with disorganized myofibrils, deficient sarcoplasmic reticulum, and blunted autonomic sympathetic innervation. Because the neonatal heart cannot significantly increase stroke volume, cardiac output is strictly heart-rate dependent, leaving infants vulnerable to tachyarrhythmias, bradycardias, and acute afterload elevation.

---

Neonatal Arrhythmias: Recognition & Electrophysiology

Supraventricular Tachycardia (SVT) vs. Sinus Tachycardia

Supraventricular Tachycardia is the most common pathological tachydysrhythmia in neonates, typically mediated by an accessory atrioventricular reentrant pathway (such as Wolff-Parkinson-White syndrome) or AV nodal reentry. Differentiating SVT from sinus tachycardia is vital:

• Supraventricular Tachycardia (SVT): Rapid, unvarying, narrow-complex ventricular rate, typically 220 to 300 bpm. Features abrupt onset and termination ("on-off switch" kinetics). P waves are absent, obscured in the preceding T wave, or inverted (retrograde conduction). Decisively, SVT exhibits complete loss of physiological beat-to-beat variability during handling or rest.
• Sinus Tachycardia: Ventricular rate usually <200–220 bpm with smooth beat-to-beat variability fluctuating with fever, pain, agitation, or volume status. Normal upright P waves precede each narrow QRS complex.

Acute Management of Neonatal SVT

1. Vagal Maneuver (The Diving Reflex): In hemodynamically stable neonates, stimulate the trigeminal-vagal arc to slow AV nodal conduction. Apply a sealed glove or bag containing crushed ice and cold water to the forehead, nose, and upper face for 10 to 15 seconds. Never apply ocular pressure—manual compression of the globes is strictly contraindicated due to the severe risks of retinal detachment and globe rupture. Never occlude the mouth or airway.
2. Adenosine Pharmacotherapy: If vagal maneuvers fail, Adenosine is the first-line medication. Adenosine binds myocardial A1 purinergic receptors, transiently blocking AV nodal conduction:
   • Dosing: Initial dose 0.1 mg/kg rapid IV push (maximum 6 mg). If ineffective within 1–2 minutes, administer 0.2 mg/kg (maximum 12 mg).
   • Technique: Adenosine has an ultra-short half-life (<10 seconds). Administer via a two-syringe stopcock at the most proximal venous or intraosseous site, followed immediately by an instantaneous 3 to 5 mL normal saline flush. Run a continuous rhythm strip during injection to record transient AV block or asystole.
   • Contraindicated Agent: Intravenous Verapamil is strictly contraindicated in infants under 1 year of age; it causes refractory electromechanical dissociation, profound hypotension, and cardiovascular collapse.
3. Synchronized Electrical Cardioversion: If the neonate is hemodynamically unstable (hypotension, poor perfusion, lethargy, pulmonary edema, or cardiogenic shock), perform immediate synchronized cardioversion at 0.5 to 1.0 J/kg. If refractory, escalate to 2.0 J/kg. Ensure SYNC mode is engaged to deliver the shock on the R wave, preventing the lethal "R-on-T" phenomenon that triggers ventricular fibrillation.

Neonatal Bradycardia & Congenital Complete Heart Block

• Secondary Bradycardia: Neonatal bradycardia (heart rate <100 bpm, or <60 bpm requiring chest compressions) is almost universally secondary to hypoxemia, alveolar hypoventilation, or severe acidosis. The immediate, definitive treatment is establishing airway patency and delivering effective positive pressure ventilation (PPV) with supplemental oxygen. Atropine and chronotropes are ineffective if hypoxia and acidosis remain uncorrected.
• Congenital Complete Heart Block (CCHB): A critical exception caused by transplacental transfer of maternal autoantibodies (anti-Ro/SSA and anti-La/SSB) from mothers with systemic lupus erythematosus or Sjögren's syndrome. Autoantibodies induce inflammation and irreversible calcification of the fetal AV node and bundle of His.
  • Features: Fixed, profound resting bradycardia (typically 40 to 70 bpm) with complete AV dissociation, usually with a narrow-QRS junctional escape rhythm.
  • Management: Unresponsive to atropine due to anatomical nodal disruption. Chronotropic infusions like Isoproterenol (0.05–0.5 mcg/kg/min) or Epinephrine (0.05–0.3 mcg/kg/min) stimulate the escape pacemaker. For low cardiac output or hypotension, emergent transcutaneous or temporary pacing is indicated.

---

Neonatal Cardiogenic Shock vs. Septic Shock

Differentiating cardiogenic from septic shock is critical to avoid lethal fluid overload:

Targeted Inotropic Support for the Failing Myocardium

Because the neonatal ventricle operates near the peak of its Frank-Starling curve, fluid boluses in cardiogenic shock exacerbate ventricular dilation and alveolar flooding. Fluid boluses must be strictly restricted (5 mL/kg aliquots only if true hypovolemia is documented). Inotropic therapies include:

• Milrinone (0.25 to 0.75 mcg/kg/min): PDE-3 inhibitor that enhances contractility, accelerates diastolic relaxation (lusitropy), and decreases SVR and PVR (inodilator) without increasing myocardial oxygen consumption. In transport, omit the loading bolus to avoid sudden vasodilation and hypotension.
• Dobutamine (2 to 20 mcg/kg/min): Beta-1 inotrope with mild beta-2 vasodilation, augmenting cardiac output while reducing filling pressures.
• Low-Dose Epinephrine (0.03 to 0.1 mcg/kg/min): Provides direct beta-1 receptor stimulation, bypassing depleted neonatal norepinephrine stores. Avoid pure alpha-agonists that elevate afterload against a failing ventricle.

---

Post-Resuscitation Critical Care in Transport

1. Targeted Temperature Management: Strict avoidance of hyperthermia ($T > 38.0^\circ\text{C}$) is mandatory; fever accelerates cerebral metabolic oxygen consumption ($CMRO_2$) and worsens post-ischemic neuronal death. Maintain core normothermia ($36.5^\circ\text{C}$ to $37.5^\circ\text{C}$), or initiate active therapeutic hypothermia ($33.5^\circ\text{C}$) if the infant meets criteria for moderate-to-severe hypoxic-ischemic encephalopathy (HIE).
2. Metabolic & Glycemic Homeostasis: Maintain blood glucose strictly between 70 and 120 mg/dL with continuous dextrose infusions (GIR 4–8 mg/kg/min). Hypoglycemia (<45–50 mg/dL) causes neuronal apoptosis, while hyperglycemia (>150–180 mg/dL) exacerbates cerebral lactic acidosis.
3. Invasive Hemodynamic Monitoring: Secure an umbilical arterial catheter (UAC) or peripheral arterial line for continuous mean arterial pressure (MAP) monitoring, targeting a MAP $\ge$ gestational age in weeks (or $\ge 40–45\text{ mmHg}$ in term infants). Track serial lactate clearance and monitor hourly urine output, targeting >1–2 mL/kg/hr as the benchmark of visceral perfusion.

---

Comparison of Neonatal Arrhythmias & Shock States

---

Realistic Transport Scenario: Unstable Neonatal SVT Conversion En Route

A neonatal transport crew is transferring a 10-day-old infant (weight 3.5 kg) to a pediatric cardiac ICU. En route, the cardiac monitor alarms for a sudden change from sinus rhythm (145 bpm) to an unvarying narrow-complex tachycardia at 290 bpm. Over 3 minutes, the infant becomes pale and lethargic, capillary refill extends to 4.5 seconds, and blood pressure drops to 48/26 mmHg (mean 33 mmHg). The transport physician immediately identifies unstable SVT. The team attaches pediatric defibrillator pads, verifies 'SYNC' mode, and charges to 3 Joules (~0.85 J/kg). A single synchronized shock is delivered, producing brief sinus pauses followed by normal sinus rhythm at 150 bpm. Blood pressure rapidly improves to 72/44 mmHg (mean 53 mmHg) and capillary refill shortens to 2 seconds, stabilizing the infant for transit.

---

Clinical Pearls for Arrhythmias & Cardiogenic Shock